 RADNOR, Pa., Aug. 30, 2021 PRNewswire -- NRx Pharmaceuticals NRx Nasdaq: NRXP announced an additional finding in its phase 2b3 clinical trial investigating ZYESAMITM aviptadil for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. 